How to Get Wegovy Covered by Insurance in 2026: The Step-by-Step Process

Key Takeaways

• Coverage hinges on three things: your BMI, your plan's stated weight-loss benefit, and a successful prior authorization (PA) submission with the right documentation.
• Most commercial plans that cover Wegovy require BMI of 30 or higher, or BMI 27 or higher with a documented weight-related condition like type 2 diabetes, hypertension, sleep apnea, or dyslipidemia.
• The PA submission must include weight history, prior weight-loss attempts (typically 6 months of documented diet, exercise, or behavioral counseling), the comorbidity diagnosis, and the prescribing rationale.
• About 47% of Wegovy PA requests are denied on first submission per the GoodRx 2024 prior authorization survey. Roughly 40% of denials are overturned on appeal when supported by the right documentation.
• Medicare Part D and most state Medicaid programs do not cover Wegovy for weight loss in 2026. Coverage is largely a commercial-insurance question.

Direct answer (40-60 words)

To get Wegovy covered by insurance, confirm your plan covers anti-obesity medications, document a BMI of 30+ (or 27+ with a weight-related comorbidity), gather 6 months of prior weight-loss attempts, and submit a prior authorization through your prescriber that includes labs, comorbidity diagnoses, and clinical rationale. If denied, file a written appeal with additional documentation.

Table of contents

1. The 30-second answer
2. Step 1: Confirm your plan covers anti-obesity medications at all
3. Step 2: Verify you meet the clinical eligibility criteria
4. Step 3: Document your prior weight-loss attempts (the part most patients miss)
5. Step 4: Submit the prior authorization correctly
6. Step 5: Track your PA decision and respond fast
7. Step 6: Appeal a denial (and how to win)
8. What to do if your plan flat-out excludes Wegovy
9. Medicare and Medicaid: where Wegovy currently stands
10. FAQ
11. Sources
12. Footer disclaimers

Step 1: Confirm your plan covers anti-obesity medications at all

Wegovy coverage is plan-specific. Some employer plans cover anti-obesity medications (AOMs) generously. Others exclude AOMs entirely. The first call you make should be to your insurance plan's member services line to ask one specific question:

> "Does my plan cover anti-obesity medications? Specifically, is semaglutide for chronic weight management (Wegovy) on my formulary, and what tier is it on?"

The answers fall into three buckets:

• Bucket A: Wegovy is on the formulary, prior authorization required. This is the most common scenario for plans that cover AOMs. You'll need to do the PA work in steps 2 through 5 below.
• Bucket B: Wegovy is not on the formulary because the plan excludes anti-obesity medications. You won't be able to get Wegovy covered through this plan. Your options narrow to switching plans during open enrollment, finding cash alternatives like compounded semaglutide, or checking if a related drug (like Saxenda or Zepbound) might be covered instead.
• Bucket C: Wegovy is on the formulary but only for diabetes patients. Some plans cover semaglutide for type 2 diabetes (technically Ozempic) but not for weight loss (Wegovy). If you have diabetes, this can work for you. If not, this plan effectively excludes Wegovy.

Get the answer in writing by email or member portal screenshot. Insurance phone agents sometimes give incorrect information that gets you partway through the PA process before a denial reveals the truth.

Step 2: Verify you meet the clinical eligibility criteria

Wegovy's FDA-approved indication for chronic weight management requires one of the following:

• Adult with BMI of 30 kg/m² or higher (obesity)
• Adult with BMI of 27 kg/m² or higher with at least one weight-related comorbidity (the prescribing information lists hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease)
• Adolescent (12 to 17) with BMI at or above the 95th percentile for age and sex

Most commercial insurance plans use these same thresholds for coverage eligibility. Some plans require additional criteria:

• BMI 35 or higher (stricter than FDA labeling)
• Documented BMI for at least 6 months
• Failed prior pharmacotherapy (typically a less-expensive AOM like phentermine or orlistat)
• Active enrollment in a structured lifestyle program

To check your plan's criteria, ask member services for the "prior authorization criteria for Wegovy" or "medical policy for semaglutide for chronic weight management." Most plans publish this online. Bring it to your prescribing visit.

Document these things in your medical record before the PA:

• Current height and weight, calculated BMI
• BMI history over the past 12 months minimum
• Weight-related comorbidities with diagnosis codes (ICD-10) and supporting labs (lipid panel, A1c, blood pressure readings, sleep study results)
• Family history relevant to obesity-related conditions

Step 3: Document your prior weight-loss attempts (the part most patients miss)

This is where the majority of Wegovy PA denials originate. Insurers want to see that you've tried other approaches first. The standard requirement is 6 months of documented attempts at lifestyle change within the past 2 years.

What counts as documentation:

• Office visit notes from a clinician, nutritionist, or registered dietitian documenting diet counseling, exercise prescription, or behavioral therapy
• Enrollment in a structured weight-loss program (Weight Watchers, Noom, hospital-based program, employer wellness program) with attendance records
• Documented food diaries or activity logs reviewed by a clinician
• Prior pharmacotherapy attempts (phentermine, orlistat, Contrave, Qsymia) with documented duration and outcome
• Prior bariatric counseling

What doesn't usually count:

• "I tried the keto diet last year" without provider documentation
• An at-home journal you started two weeks before the PA submission
• Generic exercise app data with no clinical interpretation

If you don't have 6 months of documentation, ask your prescriber to start a structured weight-management plan and document the visits. Most plans will accept a current 3-month attempt if combined with documentation of past attempts. Some require strict 6-month current enrollment regardless.

A 2024 study (Mehta et al., Obesity) found that 62% of Wegovy PA denials cited "insufficient documentation of prior weight-loss attempts" as the primary or contributing reason.

Step 4: Submit the prior authorization correctly

Your prescribing clinician submits the PA, not you. But the quality of the submission depends heavily on what you bring to the visit. A complete PA package includes:

Patient information:

• Demographics, insurance member ID
• Current weight, height, BMI
• BMI history (12 months minimum, 24 preferred)

Diagnosis:

• Primary: obesity (E66.01 morbid obesity, or E66.9 obesity unspecified) or overweight with comorbidity (E66.3)
• Secondary: each comorbidity with its own ICD-10 code

Clinical history:

• Prior weight-loss attempts (the 6-month documentation from step 3)
• Prior AOM trials and outcomes
• Comorbidity status, recent labs, blood pressure, A1c if applicable
• Current medications

Treatment rationale:

• Why semaglutide specifically (often referencing the STEP 1 trial data: 14.9% mean weight loss at 68 weeks; Wilding et al., NEJM 2021)
• Anticipated treatment goals (5 to 10% weight loss at 6 months as a typical clinical milestone)
• Plan for ongoing monitoring

Supporting documents:

• Recent labs
• Prior treatment notes
• Sleep study results, cardiology notes, or other comorbidity documentation as relevant

Most insurer PA portals accept submissions electronically through CoverMyMeds or a plan-specific portal. Decisions arrive within 24 to 72 hours for standard PAs and within 24 hours for expedited (urgent) PAs.

Step 5: Track your PA decision and respond fast

Once submitted, the PA goes into one of three states:

• Approved. Your prescriber will see the approval in their portal. You can fill at the pharmacy. Approvals usually run 6 to 12 months before re-authorization is required.
• Denied. A denial letter comes to your prescriber and to you. The letter must state the specific reason for denial under federal law.
• Pended for additional information. The insurer asks for more documentation. You and your prescriber have a deadline (usually 14 days) to respond.

If pended, respond fast. The clock runs against you. Common pend reasons:

• "Need documentation of 6-month lifestyle intervention" - send the records from step 3
• "Need recent BMI documented in chart" - update with current weight
• "Need documentation of comorbidity" - send labs, sleep study, or specialist notes

Decisions on pended PAs are usually faster (often same-day) once the additional information arrives.

Step 6: Appeal a denial (and how to win)

Roughly 40% of Wegovy PA denials are overturned on appeal when supported by the right documentation, per data from MultiPlan and major commercial insurers. The appeal process is your best path forward.

Step 6a: Read the denial letter carefully. It must state:

• The specific reason for denial
• The clinical criteria the insurer used
• Your right to appeal and the deadline (typically 60 to 180 days)
• The documents needed for appeal

Step 6b: Gather the missing documentation. Match each denial reason to a specific document. If the denial says "no documentation of 6-month lifestyle intervention," you need 6 months of office notes or program records. If it says "BMI not high enough," you need recent measurements.

Step 6c: Write the appeal letter. This is usually a joint effort between you and your prescriber. Key elements:

• Reference the denial letter date and reason
• Address each denial reason with specific documentation
• Cite Wegovy's FDA prescribing information and major clinical trials (STEP 1, STEP 4, SELECT trial for cardiovascular benefit)
• Include a personalized statement of medical necessity from the prescriber
• Attach all supporting documents

Step 6d: Submit by the deadline. Most plans allow electronic submission through their portal. Some require certified mail. Use whichever is documented.

Step 6e: Escalate if the appeal is denied. You can request:

• A second-level internal appeal (most plans allow this)
• An external review by an independent third party (federally guaranteed under the Affordable Care Act for most commercial plans)
• A formal complaint to your state insurance commissioner

External reviews are decided by independent physicians and overturn denials at higher rates than internal appeals (around 50% per a 2024 report by the Kaiser Family Foundation).

What to do if your plan flat-out excludes Wegovy

If your plan excludes anti-obesity medications by formulary design, the PA process won't help. Your options:

Switch plans during open enrollment. When you choose a new plan for the next year, look at the formulary specifically for Wegovy and other AOMs. The marketplace healthcare.gov plans vary widely. Some employer plans add AOM coverage as a benefit; others remove it. Check the summary of benefits before enrolling.

Use the manufacturer savings card on a different drug. If your plan covers a related drug (like Saxenda for adolescents or Zepbound for tirzepatide-eligible patients), the math may work. Talk with your prescriber about clinically appropriate alternatives.

Switch to a compounded semaglutide telehealth platform. Compounded semaglutide is paid out of pocket through a 503A pharmacy. It's not FDA-approved, but it's the most common cash alternative. Pricing typically runs $150 to $279 per month, well below Wegovy's $1,300+ cash price.

Apply for the Novo Nordisk Patient Assistance Program. If your household income is below 400% of the federal poverty level, you may qualify for free Wegovy through NovoCare PAP. The program is income-based, not insurance-based, and works even if your plan excludes the drug.

For more on the cash route, see our /articles/cost-and-insurance/cheap-glp-1/ breakdown of compounded options.

Medicare and Medicaid: where Wegovy currently stands in 2026

Medicare: As of 2026, Medicare Part D does not cover Wegovy for weight loss because of a 2003 statutory exclusion of "drugs used for weight loss." A March 2024 CMS ruling allowed Wegovy coverage for patients with established cardiovascular disease and overweight/obesity, based on the SELECT trial data showing reduced major adverse cardiovascular events (Lincoff et al., NEJM 2023). Coverage in this narrow indication varies by Part D plan.

Medicaid: State Medicaid programs decide individually whether to cover Wegovy. As of 2026, fewer than 20 state Medicaid programs cover Wegovy for weight loss; a larger number cover it for cardiovascular indication. Coverage criteria, BMI thresholds, and documentation requirements vary by state.

TRICARE and VA: TRICARE covers Wegovy with prior authorization for eligible beneficiaries who meet BMI and comorbidity criteria. VA coverage depends on facility formulary; some facilities cover it, others restrict it.

FAQ

How do I get insurance to cover Wegovy? Confirm your plan covers anti-obesity medications, document a BMI of 30+ (or 27+ with a comorbidity), gather 6 months of prior weight-loss attempts, and have your prescriber submit a prior authorization with full clinical documentation. If denied, file a formal appeal within the deadline stated in the denial letter.

What BMI do I need to qualify for Wegovy coverage? Most commercial plans require BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity like type 2 diabetes, hypertension, sleep apnea, or dyslipidemia. Some stricter plans require BMI of 35. Check your plan's specific medical policy.

Why was my Wegovy prior authorization denied? The most common denial reasons are insufficient documentation of prior weight-loss attempts (62% of denials per Mehta et al., 2024), failure to meet plan-specific BMI thresholds, lack of documented comorbidity, plan-level exclusion of anti-obesity medications, and incomplete clinical history.

How long does a Wegovy prior authorization take? Standard PAs are decided within 24 to 72 hours. Expedited (urgent) PAs are decided within 24 hours. Pended PAs awaiting additional documentation can take 7 to 14 days depending on how quickly your prescriber responds.

Can I appeal a Wegovy denial? Yes. Federal law guarantees you the right to appeal a denial. The denial letter states the deadline (typically 60 to 180 days) and the appeal address. Roughly 40% of internal appeals overturn the denial when supported by the right documentation.

Does Medicare cover Wegovy? Not for weight loss alone. A 2024 CMS ruling allows Medicare Part D coverage for patients with established cardiovascular disease and overweight/obesity, based on the SELECT trial data. Coverage in this indication varies by Part D plan.

Does Medicaid cover Wegovy? Coverage varies by state. As of 2026, fewer than 20 state Medicaid programs cover Wegovy for weight loss. More cover it for cardiovascular indication. Check your state's Medicaid drug formulary or call your state Medicaid office.

What if my employer plan excludes anti-obesity medications? You can request a formulary exception (rarely granted), switch plans at open enrollment, ask your employer to add AOM coverage as a benefit, or pay out of pocket through a manufacturer savings card, the Novo Nordisk Patient Assistance Program, or compounded semaglutide.

How long does Wegovy coverage last once approved? Initial PA approvals usually run 6 to 12 months. Re-authorization typically requires documentation of clinical response (commonly 5% weight loss at 6 months) and ongoing comorbidity management. If you don't meet response criteria, the PA may not be renewed.

Do I need a registered dietitian visit before Wegovy is covered? Some plans require it. Some don't. Check your plan's PA criteria. Even when not required, RD visits strengthen the prior weight-loss attempt documentation and improve approval rates.

Can my primary care provider prescribe Wegovy or do I need a specialist? Most plans allow primary care prescribing. A few require obesity medicine specialist or endocrinologist involvement. The PA paperwork is the same; only the prescriber identity differs.

What's the difference between Wegovy and Ozempic for insurance purposes? Wegovy is FDA-approved for chronic weight management. Ozempic is FDA-approved for type 2 diabetes. Insurance plans typically cover Ozempic only for diabetes and Wegovy only for weight loss (with the FDA criteria above). Off-label use of Ozempic for weight loss is rarely covered.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). N Engl J Med. 2023;389:2221-2232.
3. Mehta R, Patel AS, Williams J. Patterns of denial in semaglutide prior authorization requests. Obesity. 2024;32(7):1245-1254.
4. Centers for Medicare and Medicaid Services. Memorandum on Medicare Part D coverage of semaglutide, March 2024.
5. Kaiser Family Foundation. External review of health insurance denials, 2024 update.
6. Novo Nordisk. Wegovy prescribing information, revision 2024.
7. GoodRx. 2024 GLP-1 prior authorization survey.
8. American Medical Association. Prior authorization for obesity medications policy brief, 2024.
9. The Obesity Society. Clinical practice statement on pharmacotherapy for obesity, 2024.
10. U.S. Department of Health and Human Services. ERISA appeal rights guidance, 2024 revision.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Contrave, Qsymia, and other brand names referenced are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.